Shifa Biomedical Pcsk9

At Manningham Medical Centre, you can find all the data about Shifa Biomedical Pcsk9. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.

Product - shifabiomedical.com

http://shifabiomedical.com/product.html

Figure 1: A diagrammatic representation of the LDLR pathway. Shifa has undertaken two complementary, parallel approaches for developing compounds that interfere with PCSK9 function. These …

shifabiomedical.com - Home

http://shifabiomedical.com/index.html

Shifa Biomedical Corporation (Shifa) is a drug discovery company in Malvern Pennsylvania. It is a privately held biopharmaceutical company dedicated to the cost-effective development of drugs for …

Shifa Launches with Seed Financing to Address ... - Business Wire

https://www.businesswire.com/news/home/20210512005300/en/Shifa-Launches-with-Seed-Financing-to-Address-Cardiovascular-Disease-by-Developing-Orally-Bioavailable-Drugs-for-the-Treatment-of-Dyslipidemia

Shifa’s lead molecule, P-21, acts as a PCSK9/LDLR-antagonist to modulate the degradation of the LDLR in the liver, thereby regulating cholesterol homeostasis. With …

Shifa Launches with Seed Financing to Address

https://xontogeny.com/news/shifa-launches-with-seed-financing-to-address-cardiovascular-disease-by-developing-orally-bioavailable-drugs-for-the-treatment-of-dyslipidemia/

Shifa Biomedical Corporation (Shifa) is a drug discovery company in Malvern Pennsylvania. It is a privately held biopharmaceutical company dedicated to the cost …

Novel oral nano-hepatic targeted anti-PCSK9 in

https://pubmed.ncbi.nlm.nih.gov/34748962/

The development of anti-PCSK9 therapeutics attracted considerable attention for the management of cardiovascular disease risk. However, only subcutaneous injectable …

Shifa Biomedical Corporation Presents Preclinical Data on

https://www.globenewswire.com/news-release/2018/11/12/1649923/0/en/Shifa-Biomedical-Corporation-Presents-Preclinical-Data-on-P-21-a-Novel-Orally-Active-PSCK9-Antagonist-at-the-American-Heart-Association-AHA-Meeting-Scientific-Sessions-2018.html

Shifa Biomedical successfully identified a potent orally bioavailable small molecule PCSK9 antagonist. This lead molecule (P-21) was identified through virtual screening of a million...

Shifa Biomedical at Bio Boston: New Oral PCSK9 Inhibitor

https://www.linkedin.com/pulse/shifa-biomedical-bio-boston-new-oral-pcsk9-inhibitor-paul-jeffrey

Shifa has developed a series of novel, first-in-class oral medicines using a novel proprietary hybrid in-silico and cell-based screening method. These small molecule …

Research programme: PCSK9 protein inhibitors - Shifa …

https://adisinsight.springer.com/drugs/800042164

Shifa Biomedical is developing PCSK9 inhibitors for the treatment of cardiovascular disorders including hypercholesterolaemia. A member of the proprotein …

Targeting PCSK9 as a promising new mechanism for …

https://pubmed.ncbi.nlm.nih.gov/27133571/

PCSK9 is a protease involved in chaperoning the low-density lipoprotein receptor to the process of degradation. PCSK9 inhibitors and statins effectively lower LDL-C. The …

P 21 - Shifa Biomedical - AdisInsight - Springer

https://adisinsight.springer.com/drugs/800063747

Originator Shifa Biomedical. Class Antihyperlipidaemics; Small molecules. Mechanism of Action LDL receptor antagonists; PCSK9 protein inhibitors. Orphan Drug Status. Orphan …

Need more information about Shifa Biomedical Pcsk9?

At Manningham Medical Centre, we collected data on more than just Shifa Biomedical Pcsk9. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.